Results Evaluation of outcomes of gestation showed that in 9 cases, there has been a termination of pregnancy in the 1st trimester due to the high activity of SLE. They were mostly women with active lupus nephritis (7), one case with massive exudative pericarditis and one patient with lupus hepatitis. Pregnancy in 6 women on the background of a moderate (2) and minimal disease activity (4), with a primary skin (4) and articular syndrome (1), with the trace proteinuria (1) completed delivery of healthy children in the gestation of 36 to 38 weeks. In 3 of them - by Caesarean section, in 3 others - it was delivery was vaginally at 39 weeks gestation. 27 did not have children because of the risk of adverse effects of pregnancy on the course of the disease; the other 27 women had children prior to the development of SLE.

Conclusions Half of the women (52%) was not able to have children due to the high risk of adverse effects of pregnancy on the course of the disease, with active SLE caused the interruption of pregnancy in 13% of patients.

Background and aims Systemic Lupus Erythematosus (SLE) is a multisystem autoimmune disease which commonly affects women of childbearing age. There were reports of the adverse pregnancy outcome in SLE patients but data from Indonesia was still lacking. The objectives of this study were to analyse pregnancy outcome in SLE patients but data from Indonesia women of childbearing age. There were reports of the adverse multisystem autoimmune disease which commonly affects women of childbearing age.

Methods This was a retrospective study of pregnant SLE patients in Indonesian national referral hospital from 2012–2015. Medical records of all pregnant SLE patients who gave birth in our centre during that period were reviewed. Independent variables were previous and current nephritides, history of adverse pregnancy outcome, pre-pregnancy hypertension, and disease control during pregnancy. Dependent variables were maternal complications (ICU admission, SLE flare, hypertension/eclampsia/preeclampsia, and death) and fetal/neonatal complications (low birth weight, oligohydramnios, and abortion/fetal death/neonatal death).

Results There were 32 pregnancies of which 13 were first pregnancies. Preterm deliveries were observed in 37.5% patients and 66.7% patients were delivered by C-section. Eight patients (25%) experienced maternal complications with 1 patient died due to heart failure. There were 71.9% pregnancies with fetal/neonatal complications and among those, low birth weight was the main complication (39.1%). There were significant association between disease control during pregnancy and maternal complications (p=0.029) and between history of adverse pregnancy outcome and fetal/neonatal complications (p=0.005).

Conclusions The rate of maternal and fetal/neonatal complications was high. Pregnant SLE patients need to be monitored closely especially those with uncontrolled disease during pregnancy and history of adverse pregnancy outcome.

Background and aims SLE often affects women of childbearing age. Prednisone is safely used during pregnancy. Modified-release prednisone (MRP) is a treatment option, but no data exist regarding gestation: we aimed to compare its safety and effectiveness to the immediate release formulation (IRP) in SLE pregnancies.

Methods During a 5 year period, we enrolled 18 SLE female patients experiencing a pregnancy. Nine (cases), taking low-dose MRP (5 to 7.5 mg/daily) as a baseline treatment, were matched to 9 controls (same age and disease duration), taking the same prednisone dose in the IR formulation. Pregnancy outcome; SLEDAI/SLEPDAI; patient’s VS and need of treatment changes were assessed at baseline, during pregnancy and at postpartum.

Results SLEDAI at baseline was 2±0.1 among MPR and 2±0.3 among IR women; SLEPDAI, 3±0.9 and 3±0.2 (both, p=ns). No major perinatal complications were detected. Preterm births, caesarean section rates, newborns weight and APGAR scores did not differ between the two subpopulations (all, p=ns). SLEDAI at postpartum was 3.8±0.6 in MRP subjects and 5.4±0.4 in IR (p<0.05). Patients’ VS evaluation (MRP vs IR) was, respectively, 30±4 and 20±9 at baseline (p=ns), 30±6 and 48±7 during pregnancy (p<0.05) and 31±3 and 52±9 at postpartum (p<0.05). Prednisone regimen changes (add-on strategy), the observed rates matched to 9 controls (same age and disease duration), taking the same prednisone dose in the IR formulation. Pregnancy outcome; SLEDAI/SLEPDAI; patient’s VS and need of treatment changes were assessed at baseline, during pregnancy and at postpartum.

Conclusions Among IR patients, activity was significantly higher during postpartum and treatment had to be increased. VS was significantly different (higher among IR), both during pregnancy and postpartum. MRP seems to be as safe, but more effective, in comparison the IR, during pregnancy of SLE women.

Background and aims To evaluate the course of pregnancy associated with systemic lupus erythematosus (SLE).

Methods We picked up retrospectively the patients with SLE who was in pregnant. We studied the courses of pregnancy, the results of delivery, and the states of babies.

Results We found 35 courses of pregnancy associated with SLE. Twenty-six patients with SLE experienced pregnancy. Thirty-six babies were born through 35 courses of pregnancy (including a pair of twin). Early deliveries were found in 5 (including a pair of twin). Low weight born were found